Ocular surface complications following biological therapy for cancer

Frontiers in Toxicology

Toxicology

Tina Yi-Jin Hsieh¹  Kevin Sheng-Kai Ma²  James Chodosh³  Ping-Feng Tsai⁴ 

[1] Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, United States;Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA, United States;Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States;Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States;Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States;Department of Ophthalmology and Visual Sciences, University of New Mexico School of Medicine, Albuquerque, NM, United States;Department of Ophthalmology, Tri-Service General Hospital, Taipei, Taiwan;

关键词: biological therapy;    cancer;    cornea;    immunotherapy;    ocular surface;    targeted therapy;   

DOI  :  10.3389/ftox.2023.1137637

 received in 2023-01-04, accepted in 2023-06-12,  发布年份 2023

来源: Frontiers

【 摘 要 】

Novel and highly effective biological agents developed to treat cancer over the past two decades have also been linked to multiple adverse outcomes, including unanticipated consequences for the cornea. This review provides an overview of adverse corneal complications of biological agents currently in use for the treatment of cancer. Epidermal growth factor receptor inhibitors and immune checkpoint inhibitors are the two classes of biological agents most frequently associated with corneal adverse events. Dry eye, Stevens-Johnson syndrome, and corneal transplant rejection have all been reported following the use of immune checkpoint inhibitors. The management of these adverse events requires close collaboration between ophthalmologists, dermatologists, and oncologists. This review focuses in depth on the epidemiology, pathophysiology, and management of ocular surface complications of biological therapies against cancer.

【 授权许可】

Unknown   
Copyright © 2023 Ma, Tsai, Hsieh and Chodosh.